Craig Titmus

Craig’s practice covers diverse biotechnological subject-matter, with a particular focus on vaccines, diagnostics, therapeutic antibodies and peptide conjugates and biofuels. Craig has significant experience of European and international patent prosecution, and coordinates global IP strategies for a range of clients including start-ups, SMEs, universities, large corporations and the UK Government.  

Craig gained a first class bachelor’s degree in molecular biology and biochemistry at the University of Durham where he ranked top in his year. He went on to the University of Cambridge to undertake a PhD in collaboration with a multinational crop research company, focusing on environmental stress tolerance in plants and the interfaces between metabolism and the cell cycle. During his time at Cambridge, Craig was awarded various PhD prizes within the Institute of Biotechnology. He also holds a certificate in Intellectual Property from the University of London as well as an Intellectual Property Litigation Certificate.

Craig has presented on the challenges of stem cell patentability in Europe and provided practical advice on how to obtain commercially-relevant patents in this technical field.  A link to the full presentation is provided below.

European and US Patent Strategies for Cell Therapies

Craig is a member of CIPA, EPI and has been appointed One Nucleus’ IP Mentor, as well as a recommended individual by IAM1000.